Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SH, Salgia R, Brennan T, Chalmers ZR, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller VA. Frampton GM, et al. Among authors: peters m. Cancer Discov. 2015 Aug;5(8):850-9. doi: 10.1158/2159-8290.CD-15-0285. Epub 2015 May 13. Cancer Discov. 2015. PMID: 25971938
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M. Krepler C, et al. Among authors: peters m. Clin Cancer Res. 2016 Apr 1;22(7):1592-602. doi: 10.1158/1078-0432.CCR-15-1762. Epub 2015 Dec 16. Clin Cancer Res. 2016. PMID: 26673799 Free PMC article.
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.
Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, Ebbesen SH, Ainscough BJ, Ramu A, Iyer G, Shah RH, Huynh T, Mino-Kenudson M, Sgroi D, Isakoff S, Thabet A, Elamine L, Solit DB, Lowe SW, Quadt C, Peters M, Derti A, Schegel R, Huang A, Mardis ER, Berger MF, Baselga J, Scaltriti M. Juric D, et al. Among authors: peters m. Nature. 2015 Feb 12;518(7538):240-4. doi: 10.1038/nature13948. Epub 2014 Nov 17. Nature. 2015. PMID: 25409150 Free PMC article.
Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma.
Hart LS, Rader J, Raman P, Batra V, Russell MR, Tsang M, Gagliardi M, Chen L, Martinez D, Li Y, Wood A, Kim S, Parasuraman S, Delach S, Cole KA, Krupa S, Boehm M, Peters M, Caponigro G, Maris JM. Hart LS, et al. Among authors: peters m. Clin Cancer Res. 2017 Apr 1;23(7):1785-1796. doi: 10.1158/1078-0432.CCR-16-1131. Epub 2016 Oct 11. Clin Cancer Res. 2017. PMID: 27729458
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R. Ascierto PA, et al. Among authors: peters m. Lancet Oncol. 2013 Mar;14(3):249-56. doi: 10.1016/S1470-2045(13)70024-X. Epub 2013 Feb 13. Lancet Oncol. 2013. PMID: 23414587 Clinical Trial.
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, Van Cutsem E, Pérez-García J, Stathis A, Britten CD, Le N, Carter K, Demanse D, Csonka D, Peters M, Zubel A, Nauwelaerts H, Sessa C. Bedard PL, et al. Among authors: peters m. Clin Cancer Res. 2015 Feb 15;21(4):730-8. doi: 10.1158/1078-0432.CCR-14-1814. Epub 2014 Dec 10. Clin Cancer Res. 2015. PMID: 25500057 Clinical Trial.
Building global collaborative research networks in paediatric critical care: a roadmap.
Schlapbach LJ, Ramnarayan P, Gibbons KS, Morrow BM, Napolitano N, Tume LN, Argent AC, Deep A, Lee JH, Peters MJ, Agus MSD, Appiah JA, Armstrong J, Bacha T, Butt W, de Souza DC, Fernández-Sarmiento J, Flori HR, Fontela P, Gelbart B, González-Dambrauskas S, Ikeyama T, Jabornisky R, Jayashree M, Kazzaz YM, Kneyber MCJ, Long D, Njirimmadzi J, Samransamruajkit R, Asperen RMW, Wang Q, O'Hearn K, Menon K; Australian and New Zealand Intensive Care Society Paediatric Study Group; Brazilian Research Network in Pediatric Intensive Care; Canadian Critical Care Trials Group; European Society of Paediatric and Neonatal Intensive Care; Pediatric Collaborative Network of Latin America; Pediatric Acute & Critical Care Medicine Asian Network; Pediatric Acute Lung Injury and Sepsis Investigators; United Kingdom Paediatric Critical Care Society Study Group; Pediatric Intensive Care Latin-American Society; World Federation of Pediatric Intensive & Critical Care Societies. Schlapbach LJ, et al. Among authors: peters mj. Lancet Child Adolesc Health. 2024 Dec 20:S2352-4642(24)00303-1. doi: 10.1016/S2352-4642(24)00303-1. Online ahead of print. Lancet Child Adolesc Health. 2024. PMID: 39718171 Review.
Hypertension and orthostatic hypotension in the elderly: a challenging balance.
Wiersinga J, Jansen S, Peters MJL, Rhodius-Meester HFM, Trappenburg MC, Claassen JAHR, Muller M. Wiersinga J, et al. Among authors: peters mjl. Lancet Reg Health Eur. 2024 Dec 3;48:101154. doi: 10.1016/j.lanepe.2024.101154. eCollection 2025 Jan. Lancet Reg Health Eur. 2024. PMID: 39717228 Free PMC article. Review.
4,181 results